Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 5
2011 7
2012 8
2013 6
2014 9
2015 8
2016 7
2017 10
2018 6
2019 11
2020 5
2021 14
2022 9
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Trends and Variation in the Use of Radiotherapy in Non-metastatic Rectal Cancer: a 14-year Nationwide Overview from the Netherlands.
Verrijssen AE, Evers J, van der Sangen M, Siesling S, Aarts MJ, Struikmans H, Bloemers MCWM, Burger JWA, Lemmens V, Braam PM, Elferink MAG, Berbee M. Verrijssen AE, et al. Among authors: aarts mj. Clin Oncol (R Coll Radiol). 2024 Apr;36(4):221-232. doi: 10.1016/j.clon.2024.01.013. Epub 2024 Jan 20. Clin Oncol (R Coll Radiol). 2024. PMID: 38336504
MATERIALS AND METHODS: Patients with non-metastasised rectal cancer in 2008-2021 (n = 37 510) were selected from the Netherlands Cancer Registry and classified into prognostic risk groups. ...Multilevel logistic regression analyses were carried out to identify facto …
MATERIALS AND METHODS: Patients with non-metastasised rectal cancer in 2008-2021 (n = 37 510) were selected from the Netherlands C …
Impact of time-to-treatment on survival for early-stage non-small cell lung cancer in The Netherlands-a nationwide observational cohort study.
Klarenbeek SE, Aarts MJ, van den Heuvel MM, Prokop M, Tummers M, Schuurbiers-Siebers OCJ. Klarenbeek SE, et al. Among authors: aarts mj. Transl Lung Cancer Res. 2023 Oct 31;12(10):2015-2029. doi: 10.21037/tlcr-23-256. Epub 2023 Oct 9. Transl Lung Cancer Res. 2023. PMID: 38025812 Free PMC article.
BACKGROUND: Varied outcomes on the relation between time-to-treatment and survival in early-stage non-small cell lung cancer (NSCLC) patients are reported. We examined this relation in a large multicentric retrospective cohort study and identified factors associated with e …
BACKGROUND: Varied outcomes on the relation between time-to-treatment and survival in early-stage non-small cell lung cancer (NSCLC) …
Socioeconomic differences in health-related quality of life among cancer survivors and comparison with a cancer-free population: a PROFILES study.
Levinsen AKG, van de Poll-Franse L, Ezendam N, Aarts MJ, Kjaer TK, Dalton SO, Oerlemans S. Levinsen AKG, et al. Among authors: aarts mj. J Cancer Surviv. 2023 Nov 29. doi: 10.1007/s11764-023-01494-y. Online ahead of print. J Cancer Surviv. 2023. PMID: 38017320
The association between SEP and HRQoL was similar in the matched cancer-free population. CONCLUSION: Low SEP was associated with impaired HRQoL in both cancer survivors and cancer-free people. IMPLICATIONS FOR CANCER SURVIVORS: Targeted care is warrant …
The association between SEP and HRQoL was similar in the matched cancer-free population. CONCLUSION: Low SEP was associated with impa …
Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands.
Noordhof AL, Swart EM, Damhuis RAM, Hendriks LEL, Kunst PWA, Aarts MJ, van Geffen WH. Noordhof AL, et al. Among authors: aarts mj. JTO Clin Res Rep. 2023 Jun 29;4(9):100543. doi: 10.1016/j.jtocrr.2023.100543. eCollection 2023 Sep. JTO Clin Res Rep. 2023. PMID: 37674812 Free PMC article.
METHODS: This nationwide population-based study used real-world data from The Netherlands Cancer Registry. We selected patients with stage IV KRAS-mutated lung adenocarcinoma diagnosed in 2019 to 2020 who received first-line (chemo-)immunotherapy. Primary outcome was OS. R …
METHODS: This nationwide population-based study used real-world data from The Netherlands Cancer Registry. We selected patients with …
Trends in the epidemiology of small-cell lung cancer: a Dutch nationwide population-based study over 1989-2020.
Dumoulin DW, Aarts MJ, De Ruysscher D, Aerts JGJV, Dingemans AC. Dumoulin DW, et al. Among authors: aarts mj. Eur J Cancer. 2023 Sep;191:112985. doi: 10.1016/j.ejca.2023.112985. Epub 2023 Jul 13. Eur J Cancer. 2023. PMID: 37524025 Free article.
INTRODUCTION: This study describes the evolving characteristics of patients with small-cell lung cancer (SCLC) from 1989 to 2020 in the Netherlands to analyse how the population of patients with SCLC has changed in the last decades, hypothesising that this might explain th …
INTRODUCTION: This study describes the evolving characteristics of patients with small-cell lung cancer (SCLC) from 1989 to 2020 in t …
The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for 'Trial within Cohorts' study designs.
Yildirim H, Widdershoven CV, Aarts MJ, Bex A, Bloemendal HJ, Bochove-Overgaauw DM, Hamberg P, Herbschleb KH, van der Hulle T, Lagerveld BW, van Oijen MG, Oosting SF, van Thienen JV, van der Veldt AA, Westgeest HM, Zeijdner EE, Aben KK, van den Hurk C, Zondervan PJ, Bins AD. Yildirim H, et al. Among authors: aarts mj. BMC Cancer. 2023 Jul 11;23(1):648. doi: 10.1186/s12885-023-11094-9. BMC Cancer. 2023. PMID: 37434119 Free PMC article.
The clinical data collection is embedded in the Netherlands Cancer Registry (NCR). Next to the standardly available data on RCC, additional clinical data will be collected. ...
The clinical data collection is embedded in the Netherlands Cancer Registry (NCR). Next to the standardly available data on RCC, addi …
Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors.
Swart EM, Noordhof AL, Damhuis RAM, Kunst PWA, De Ruysscher DKM, Hendriks LEL, van Geffen WH, Aarts MJ. Swart EM, et al. Among authors: aarts mj. Lung Cancer. 2023 Aug;182:107290. doi: 10.1016/j.lungcan.2023.107290. Epub 2023 Jul 1. Lung Cancer. 2023. PMID: 37419045
INTRODUCTION: Few data is available on whether brain metastases (BM) influence survival in patients with stage IV KRAS G12C mutated (KRAS G12C+ ) non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitor (ICI) +/- chemotherapy ([chemo]-ICI). ME …
INTRODUCTION: Few data is available on whether brain metastases (BM) influence survival in patients with stage IV KRAS G12C mutated (KRAS G1 …
Trends and variation in the use of radiotherapy in non-metastatic prostate cancer: A 12-year nationwide overview from the Netherlands.
Evers J, Kerkmeijer LGW, van den Bergh RCN, van der Sangen MJC, Hulshof MCCM, Bloemers MCWM, Siesling S, Aarts MJ, Aben KKH, Struikmans H. Evers J, et al. Among authors: aarts mj. Radiother Oncol. 2022 Dec;177:134-142. doi: 10.1016/j.radonc.2022.10.028. Epub 2022 Oct 31. Radiother Oncol. 2022. PMID: 36328090 Free article.
PURPOSE: This population-based study describes nationwide trends and variation in the use of primary radiotherapy for non-metastatic prostate cancer in The Netherlands in 2008-2019. METHODS: Prostate cancer patients were selected from the Netherlands Cancer R …
PURPOSE: This population-based study describes nationwide trends and variation in the use of primary radiotherapy for non-metastatic prostat …
Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
Steeghs EMP, Groen HJM, Schuuring E, Aarts MJ, Damhuis RAM, Voorham QJM; PATH consortium; Ligtenberg MJL, Grünberg K. Steeghs EMP, et al. Among authors: aarts mj. Lung Cancer. 2022 May;167:87-97. doi: 10.1016/j.lungcan.2022.04.001. Epub 2022 Apr 4. Lung Cancer. 2022. PMID: 35461050 Free article.
OBJECTIVES: The number of targeted drugs in non-small cell lung cancer (NSCLC) is ever-expanding and requires testing of an increasing number of predictive biomarkers. ...Linkage between the Dutch Pathology Registry and the Netherlands Cancer Registry enabled studyi …
OBJECTIVES: The number of targeted drugs in non-small cell lung cancer (NSCLC) is ever-expanding and requires testing of an increasin …
Impact of time-to-treatment on survival for advanced non-small cell lung cancer patients in the Netherlands: a nationwide observational cohort study.
Klarenbeek SE, Aarts MJ, van den Heuvel MM, Prokop M, Tummers M, Schuurbiers OCJ. Klarenbeek SE, et al. Among authors: aarts mj. Thorax. 2023 May;78(5):467-475. doi: 10.1136/thoraxjnl-2021-218059. Epub 2022 Apr 21. Thorax. 2023. PMID: 35450944
BACKGROUND: The assumption that more rapid treatment improves survival of advanced non-small cell lung cancer (NSCLC) has not yet been proven. We studied the relation between time-to-treatment and survival in advanced stage NSCLC patients in a large multicentric nationwide …
BACKGROUND: The assumption that more rapid treatment improves survival of advanced non-small cell lung cancer (NSCLC) has not yet bee …
90 results